AbbVie said it will buy cancer biotech Pharmacyclics in a $21 billion deal that returns the Chicago drug company to deal-making after backing away from a big tax-lowering takeover last year.
WSJ.com: What's News US, Wall Street Journal
Wed, 03/04/2015 - 11:55pm
AbbVie said it will buy cancer biotech Pharmacyclics in a $21 billion deal that returns the Chicago drug company to deal-making after backing away from a big tax-lowering takeover last year.